Teachers Advisors LLC boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 5.6% during the first quarter, Holdings Channel reports. The institutional investor owned 82,647 shares of the company’s stock after buying an additional 4,360 shares during the period. Teachers Advisors LLC’s holdings in Neurocrine Biosciences were worth $3,579,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BB Biotech AG boosted its position in shares of Neurocrine Biosciences by 1.6% in the first quarter. BB Biotech AG now owns 3,201,552 shares of the company’s stock valued at $138,627,000 after buying an additional 50,000 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Neurocrine Biosciences by 554.4% in the first quarter. Wellington Management Group LLP now owns 2,407,376 shares of the company’s stock valued at $104,240,000 after buying an additional 2,039,509 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Neurocrine Biosciences by 36.1% in the first quarter. Bank of New York Mellon Corp now owns 1,906,417 shares of the company’s stock valued at $82,548,000 after buying an additional 505,604 shares in the last quarter. Pictet Asset Management Ltd. boosted its position in shares of Neurocrine Biosciences by 30.0% in the first quarter. Pictet Asset Management Ltd. now owns 1,015,894 shares of the company’s stock valued at $43,988,000 after buying an additional 234,157 shares in the last quarter. Finally, Jennison Associates LLC boosted its position in shares of Neurocrine Biosciences by 76.1% in the first quarter. Jennison Associates LLC now owns 650,372 shares of the company’s stock valued at $28,161,000 after buying an additional 280,963 shares in the last quarter. 96.48% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences, Inc. (NBIX) opened at 54.78 on Thursday. The company has a 50 day moving average price of $48.15 and a 200-day moving average price of $46.63. Neurocrine Biosciences, Inc. has a 52-week low of $37.35 and a 52-week high of $55.38. The firm’s market cap is $4.83 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.01. The company had revenue of $6.34 million during the quarter, compared to analyst estimates of $0.61 million. During the same period in the previous year, the business posted ($0.46) earnings per share. Equities research analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/10/teachers-advisors-llc-increases-position-in-neurocrine-biosciences-inc-nbix.html.

NBIX has been the subject of several research reports. Bank of America Corporation initiated coverage on Neurocrine Biosciences in a research note on Friday, May 5th. They set a “buy” rating and a $70.00 target price for the company. BidaskClub raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Jefferies Group LLC raised their target price on Neurocrine Biosciences from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, April 12th. Leerink Swann decreased their target price on Neurocrine Biosciences from $68.00 to $66.00 and set an “outperform” rating for the company in a research note on Thursday, May 25th. Finally, Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $70.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, July 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seventeen have given a buy rating to the company. Neurocrine Biosciences presently has a consensus rating of “Buy” and a consensus target price of $68.25.

In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 22,500 shares of the business’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $50.00, for a total value of $1,125,000.00. Following the completion of the transaction, the insider now directly owns 154,601 shares of the company’s stock, valued at $7,730,050. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Christopher Flint Obrien sold 8,734 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $50.00, for a total value of $436,700.00. Following the completion of the transaction, the insider now directly owns 57,707 shares of the company’s stock, valued at $2,885,350. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 51,194 shares of company stock valued at $2,629,755. 4.80% of the stock is owned by insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.